Therapies that target IL-36R, such as spesolimab, could mitigate flares, address flare prevention, and provide sustained disease control in patients with GPP, presumably through rebalancing IL-36 signaling and modulating the pro-inflammatory response of downstream effectors. The gene discussed is IL1RL2; the disease is psoriasis 14, pustular.